

# HEALTHY U CHIP

## PRIOR AUTHORIZATION REQUEST FORM OPZELURA™ FOR TREATMENT OF NONSEGMENTAL VITILIGO

**For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior Authorization Department at 385-425-4052.**

**Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

If you have prior authorization questions, please call for assistance: 385-425-5094

Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		
<p><i>Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.</i></p> <p><b>Product being requested:</b> <input type="checkbox"/> Opzelura™ (ruxolitinib)</p> <p>Dosing/Frequency: _____</p>		

**If the request is for reauthorization, proceed to reauthorization section.**

Questions	Yes	No	Comments/Notes
1. Is the request by, or in consultation with, a dermatologist?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
2. Have other causes of depigmentation been ruled out (e.g., nevus depigmentosus, pityriasis alba, idiopathic guttate hypomelanosis, tinea (pityriasis) versicolor, halo nevus, piebaldism, progressive macular hypomelanosis, lichen sclerosus, chemical leukoderma, drug-induced leukoderma, hypopigmented mycosis fungoides)?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Does the affected area exceed 10% body surface area?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. Does the member have history of failure, contraindication, or intolerance to ALL of the following? <ul style="list-style-type: none"> <li>• Two medium to high potency corticosteroids (e.g., triamcinolone acetonide 0.1%, mometasone furoate 0.1%, betamethasone dipropionate 0.05%, desoximetasone 0.05%)</li> <li>• Topical calcineurin inhibitor, such as pimecrolimus or tacrolimus</li> <li>• Phototherapy</li> </ul>	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

### REAUTHORIZATION

1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does clinical documentation show achievement and maintenance of positive clinical response?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

**What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.**

Additional information:

Physician Signature:

**\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\***

Policy: PHARM-CHIP-156  
Origination Date: 07/01/2024  
Reviewed/Revised Date: 09/18/2024  
Next Review Date: 09/18/2025  
Current Effective Date: 10/01/2024

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.